Table 4.
Kinetic parameters of benzoyl–CoA and glycine for GLYAT as reported in the literature.
| Parameters | Values | Recombinant Variant/Isolated from Liver | Reference |
|---|---|---|---|
| KMapp (benzoyl-CoA) (µM) | 13 | Purified GLYAT from human liver | [33] |
| 28 ± 5 | Purified recombinant 17Ser > Thr variant | [31] | |
| 38 ± 4 | Purified recombinant 156Asn > Ser variant | [31] | |
| s 0.5 | 61 ± 3 | Purified recombinant 156Asn > Ser,199Arg > Cys variant | This study (bi-substrate Hill) |
| KMapp (benzoyl-CoA) (µM) | 67 ± 5 | Partially purified GLYAT from human liver | [32] |
| 79 ± 38 | Purified recombinant wildtype | [34] | |
| 88 ± 66 | Purified recombinant 156Asn > Ser variant | [34] | |
| s 0.5 | 97 ± 3 | Purified recombinant 156Asn > Ser variant | This study (bi-substrate Hill) |
| 118 ± 7 | Purified recombinant 17Ser > Thr,156Asn > Ser variant | This study (bi-substrate Hill) | |
| KMapp (benzoyl-CoA) (µM) | 139 ± 85 | Purified recombinant L61 variant | [34] |
| 209 | Purified recombinant 156Asn > Ser variant | [28] | |
| 57900 * | Purified GLYAT from human liver | [30] | |
| KMapp (glycine) (mM) | 6.4 | Purified GLYAT from human liver | [33] |
| 6.5 ± 1 | Partially purified GLYAT from human liver | [32] | |
| s 0.5 | 23 ± 2 | Purified recombinant 156Asn > Ser variant | This study (bi-substrate Hill) |
| KMapp (glycine) (mM) | 26.6 | Purified recombinant 156Asn > Ser variant | [28] |
| s 0.5 | 29 ± 3 | Purified recombinant 17Ser > Thr,156Asn > Ser variant | This study (bi-substrate Hill) |
| 30 ± 3 | Purified recombinant 156Asn > Ser199Arg > Cys variant | This study (bi-substrate Hill) | |
| Vmax (nmol/min/mg) | 83 ± 5 | Purified recombinant 156Asn > Ser199Arg > Cys variant | This study (bi-substrate Hill) |
| 543 ± 21 | Purified GLYAT from human liver | [33] | |
| 620 ± 20 | Purified recombinant 17Ser > Thr,156Asn > Ser variant | This study (bi-substrate Hill) | |
| 665 ± 40 | Purified recombinant 17Ser > Thr variant | [31] | |
| 807 | Recombinant 156Asn > Ser variant | [28] | |
| 850 ± 60 | Purified recombinant 156Asn > Ser variant | This study (bi-substrate Hill) | |
| 1230 | Purified recombinant 156Asn > Ser variant | [31] | |
| 17,100 # | Purified GLYAT from human liver | [30] | |
| 121,000 + | Purified recombinant L61 variant | [34] | |
| 490,000 + | Purified recombinant wildtype | [34] | |
| 1,359,000 + | Purified recombinant 156Asn > Ser variant | [34] |
* The unit reported in the article is mM; therefore, this value was converted to µM. We do think that this is either a typing or a calculation error and should be 57.9 µM but because the enzyme assay conditions are not described in the article it is difficult to ascertain where the error lies. # This error also affected the Vmax value. + These Vmax values are too high to be correct and might also be a calculation error.